from Washington University in St. Louis What did we find? Adults recently diagnosed with COVID-19 (less than 7 days) who took fluvoxamine for up to 15 days, did not show clinical deterioration. Clinical deterioration is the combination of shortness of breath and hypoxia (decrease in oxygen), which are signs of damage to the lungs. This …
Fluvoxamine for Early Treatment of COVID-19: What You Should Know Read More »
Could a drug discovered in the 1970s help tackle the Covid-19 pandemic?Why won’t they listen?Despite VERY promising results, governments and the medical machine is purposely turning a blind eye.View this drug’s live study data here In this video Bret Weinstein and Heather Heying (both PhDs in Biology) discuss ivermectin. REFERENCES: FDA’s Emergency Use Authorization Guidelines: …
In a Phase III trial, Proxalutamide reduced mortality and expedited recovery of hospitalised COVID-19 patients in Brazil. In a clinical trial, Proxalutamide reduced COVID-19 mortality risk by 92 percent and shortened the median hospital stay of patients by nine days. The investigator-initiated trial (NCT04728802), conducted by Dr Andy Goren and Dr Flávio Adsuara Cadegiani at 12 sites …
Proxalutamide reduces COVID-19 mortality risk by 92 percent Read More »
Evidence shows that this virus is engineered with Gain of Function (GoF) including mechanisms creating anInflammo Thrombotic Response (ITR) with mRNA Reverse Transcription (RT) into cell DNA with Prion-like structurespresent in the virus spike protein. Additional information Reports Angiotensin-converting enzyme 2 (ACE2) proteins of different bat species confer variable susceptibility to SARS-CoV entry Receptor usage …
By Hannah Balfour (European Pharmaceutical Review) In a Phase III trial, Proxalutamide reduced mortality and expedited recovery of hospitalised COVID-19 patients in Brazil. In a clinical trial, Proxalutamide reduced COVID-19 mortality risk by 92 percent and shortened the median hospital stay of patients by nine days. The investigator-initiated trial (NCT04728802), conducted by Dr Andy Goren and Dr …
Proxalutamide reduces COVID-19 mortality risk by 92 percent Read More »
Research, published by the Social Science Research Network, found Covid-19 patients given doses of Vitamin D were 80 per cent less likely to require ICU treatment. Those from the University of Barcelona also concluded that ‘adjusted results showed a reduced mortality of more than 60 per cent’ for those who were given the calcifediol treatment. The …
Vitamin D (calcifediol) can ‘reduce Covid deaths by up to 60% Read More »
Below is the video and slide deck of Dr. Pierre Kory’s lecture given during the January 27, 2021 webinar hosted by YPO Gold’s Southern California Chapter for hundreds of CEOs within the international YPO network. YPO is a global leadership community of chief executives with approximately 29,000 members in more than 130 countries. Dr. Kory’s …
Discussion with Dr Tess Lawrie about her META-ANALYSIS OF IVERMECTIN & EVIDENCE TO DECISION FRAMEWORK De Tess Lawrie has an MD & PhD. She grew up & studied medicine & received her PhD in South Africa, where she practised clinical medicine & surgery. She is founder & director of the Evidence Based Medical Consultancy in …
Discussion of meta-analysis & evidence to decision framework by Dr Tess Lawrie Read More »
Press Release 6 January 2021New British research has examined and pooled data from a wide range of international studies–including Argentina, Bangladesh, Iran, Pakistan, Spain, Egypt, Indiaand the US –and found that the anti-parasitic medicine Ivermectin not only reduces deaths from Covid-19, but can be used to protect doctorsand nurses–as well as others who have had …
Good news on Ivermectin for treatment of Covid-19 Read More »
As Governments and health bureaucrats claim ‘’there’s not enough evidence’’?
 
Â
